Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

CELA3B Antibodies

The chymotrypsin-like elastase family member 3B (CELA3B) protein, also known as elastase-3B, is encoded by the CELA3B gene. It is located on chromosome 1q32.1 in humans. CELA3B consists of 267 amino acids with a molecular weight of approximately 28.9 kDa. Post-translational modifications of CELA3B include phosphorylation, glycosylation, and formation of disulfide bonds. It is primarily secreted into the extracellular space rather than being membrane-bound or intracellular.

CELA3B is predominantly expressed in the pancreas, specifically in the exocrine pancreas, where it plays a crucial role in the digestion of dietary proteins. It is synthesized and stored in the zymogen granules of pancreatic acinar cells along with other digestive enzymes, such as amylase and lipase. Upon stimulation, CELA3B is released into the pancreatic ducts and subsequently into the duodenum, where it catalyzes the hydrolysis of peptide bonds in dietary proteins, aiding in their digestion and absorption in the small intestine. The expression of this protein is tightly regulated at the transcriptional and post-transcriptional levels, with factors such as hormones, cytokines, and dietary components influencing its expression.

Dysfunction or dysregulation of CELA3B has been implicated in various pancreatic diseases and conditions, particularly those involving pancreatic inflammation or injury. Elevated levels of CELA3B have been observed in acute pancreatitis, a condition characterized by inflammation of the pancreas, suggesting a potential role in disease pathogenesis. Additionally, CELA3B may contribute to pancreatic auto-digestion and tissue damage in acute pancreatitis through its proteolytic activity. Moreover, specific mutations in CELA3B or dysregulation of its expression have been associated with various health conditions. 

Given its role in pancreatic diseases, CELA3B has been investigated as a potential therapeutic target for treating pancreatitis and other pancreatic disorders. Strategies aimed at inhibiting CELA3B activity or expression, such as small molecule inhibitors or gene silencing approaches, have been explored for their potential in mitigating pancreatic inflammation and tissue damage. It is plausible that targeted therapies directed against CELA3B-overexpressing tumors or tissues may offer therapeutic benefits in specific cases. While there are ongoing efforts to develop CELA3B-targeted therapies, further research is needed to validate their efficacy and safety in clinical settings. 

Furthermore, CELA3B has been investigated as a potential biomarker for certain disease states, particularly in pancreatic cancer. Studies have demonstrated alterations in CELA3B expression levels in pancreatic cancer tissues compared to normal tissues, suggesting its potential utility as a diagnostic marker. Moreover, elevated CELA3B levels have been associated with poorer prognosis in some studies, indicating its potential as a prognostic marker. However, further research is needed to validate the clinical utility of CELA3B as a diagnostic or prognostic marker in pancreatic cancer and other diseases.

NeoBiotechnologies offers a variety of antibodies against CELA3B that have been validated for ELISA, flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting, as well as a HuProt validated option. Additionally, we hold exclusive rights to CELA3B antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/?s=Chymotrypsin-like+elastase+family+member+3B].

Synonyms

Chymotrypsin-like elastase family member 3B, Elastase IIIB, Elastase-3B, Protease E, Chymotrypsin like elastase family member 3B (CELA3B); ELA3B; Elastase IIIB; Protease E

Research Areas

Cardiovascular

Showing all 9 results

CELA3B

Showing all 9 results

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK